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Summary
Current treatments of heart transplantation are limited by incomplete effectiveness, significant toxicity, and failure to prevent chronic
rejection. Genetic manipulation of the donor heart at the time of removal offers the unique opportunity to produce a therapeutic molecule
within the graft itself, while minimizing systemic effects. Cytoprotective approaches including gene transfer of heme oxygenase (HO)-1,
endothelial nitric oxide synthase, and antisense oligodeoxynucleotides specific for nuclear factor (NF)-kB or intercellular adhesion molecule
(ICAM)-1 reduced ischaemia–reperfusion injury and delayed cardiac allograft rejection in small animals. Exogenous overexpression of
immunomodulatory cytokines such as interleukin (IL)-4, IL-10 and transforming growth factor-b, as well as gene transfer of inhibitors of
pro-inflammatory cytokines also delayed graft rejection. Gene transfer-based blockade of T-cell costimulatory activation with CTLA4-Ig or
CD40-Ig resulted in long-lasting graft survival and donor-specific unresponsiveness, as manifested by acceptance of a second graft from the
original donor strain but rejection of third-party grafts. Similar results were obtained with donor major histocompatibility complex class I
gene transfer into bone marrow cells. Gene therapy approaches to chronic rejection included gene transfer of HO-1, soluble Fas, tissue
plasminogen activator and antisense oligodeoxynucleotides specific for the anti-apoptotic mediator Bcl-x or the E2F transcription factor.
Despite major experimental advances, however, gene therapy for heart transplantation has not entered the clinical arena yet. Fundamental
questions regarding the most suitable vector, the best gene, and safety issues remain unanswered. Well-controlled studies that compare gene
therapy with established treatments in non-human primates are needed before clinical trials can be started.
q 2003 Elsevier B.V. All rights reserved.
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1. Introduction
Transplantation is the treatment of choice for end-stage
organ failure [1]. However, maintenance of a functional
allograft requires life-long immunosuppression to prevent
rejection by the immune system. Current immunosuppres-
sive drugs such as cyclosporine and corticoids act by
indiscriminately blocking T-cell activation, the primary
mechanism of graft rejection. Unfortunately, these drugs are
associated with significant side effects including renal
toxicity, dyslipidaemia, diabetes, and increased risk of
infections and malignancies. Moreover, current treatments
have failed to prevent chronic rejection, or graft arteriopathy
[2]. As a result, although 1-year survival rates for
transplanted organs now exceed 90%, overall 10-year
graft survival rates remain below 50% [3]. Clearly, novel
approaches to organ transplantation are needed.
New immunosuppressive drugs include humanized anti-
interleukin (IL)-2 receptor monoclonal antibody (daclizu-
mab) [4]; tacrolimus, which blocks IL-2-dependent T-cell
activation; mycophenolate mofetil, which blocks lympho-
cyte purine biosynthesis; and sirolimus (rapamycin), which
inhibits multiple cell cycle regulators. Initial clinical trials
have shown that the new drugs improve the short-term
outcome after organ transplantation [4,5]. However, they
are associated with significant toxicity, and their long-term
effects are unknown because the clinical follow-up is still
too short.
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Gene therapy is defined as the introduction and
expression of recombinant DNA in order to ameliorate or
cure a disease condition. The easy access to the donor
organ for genetic manipulation at the time of removal and
the need for a localized biological effect make organ
transplantation particularly well-suited to gene therapy
approaches. Indeed, ex vivo gene transfer into the donor
organ can be performed under controlled, optimized
conditions. Because the foreign gene is not directly
administered to the patient, its systemic dissemination is
minimized. Most importantly, the protective factor can be
produced for extended periods of time [6,7], potentially for
a lifetime, after a single gene administration. Obviously,
sustained production of the therapeutic molecule is of
major relevance for organ transplantation, which requires
lifelong immunosuppression.
Despite the extensive publicity devoted to gene therapy,
this field is still in its infancy. Recently, cardiovascular gene
therapy has entered the clinical arena, and promising results
have been reported in initial trials for coronary artery
disease [8]. By contrast, no clinical applications in gene
therapy for heart transplantation have been reported so far.
Nevertheless, increasing experimental evidence suggests
that this approach may be feasible. This paper is devoted
principally to a review of the theoretical basis of gene
therapy for heart transplantation, as established by exper-
imental studies in animal models.
2. Routes of gene administration
General requirements for a successful gene therapy
strategy include: (1) a suitable route of gene administration;
(2) an efficient gene transfer vector; (3) a gene product that
mediates a strong biological effect; (4) a sufficient duration
of gene expression; and (5) an acceptable risk profile.
Both systemic and localized approaches have been used
to deliver a gene of interest to the transplanted heart.
Systemic gene delivery may be suitable in the case when the
delivered gene encodes a secreted factor that acts on
neighbouring or remote cells via a paracrine mechanism.
This approach involves systemic dissemination of the
foreign gene, of course. However, targeted vectors that
bind to tissue-specific surface markers or contain tissue-
specific promoters have been developed [9]. After systemic
administration, these vectors mediate gene transfer selec-
tively to target tissues. However, targeted vectors may not
be required for gene therapy for heart transplantation
because transgene expression after ex vivo gene transfer
into the donor heart is largely confined to the graft itself.
Various routes of administration including intracoronary
infusion, intramyocardial and endomyocardial injection,
and pericardial instillation have been used to deliver a gene
of interest to the donor heart [7,10]. Using a Langendorff in
vitro perfusion system, adenovirus-mediated gene transfer
into the isolated rat heart varied as a function of vector
concentration and perfusion time [11]. Pre-treatment with
hypocalcaemic solutions, serotonin or vascular endothelial
growth factor (VEGF; originally termed vascular per-
meability factor) increases vascular permeability, poten-
tially enhancing myocardial gene transfer. Ex vivo gene
transfer by intracoronary vector infusion into the isolated
donor heart is more efficient than in vivo gene transfer by
vector instillation into the coronary circulation. This
difference is due to the long dwelling time of the vector
within the isolated donor heart, which can be equivalent to
the organ preservation time. In contrast, the transit time of
vector particles through the coronary circulation in vivo is
short, ranging from a few seconds to a few minutes during
blood flow arrest. As a result, cardiac uptake of vector
particles instilled into coronary arteries in vivo is relatively
low. As an example, the number of adenovirus genomes
after intracoronary infusion of an adenoviral vector was
33-fold lower than after intramyocardial injection in pigs
[12]. In the clinical setting, the isolated donor organ is
routinely perfused with a tissue preserving solution. This
procedure could be combined with the administration of a
therapeutic gene.
3. Gene transfer systems
Several vectors including recombinant adenovirus,
plasmid DNA, liposome–DNA and hemagglutinating
virus of Japan (HVJ)–liposome–DNA complexes have
been used to deliver a gene of interest to the donor heart
[10,13,14]. Each vector has distinct advantages and
disadvantages, and hence, a perfect vector for all appli-
cations does not exist. Instead, the vector used should be
tailored to any given application, taking into account the
cellular target, the predicted levels of transgene expression,
and the duration of expression. Accordingly, gene transfer-
based prevention of acute and chronic rejection may require
different vectors because long-term expression of the
protective gene is highly desirable in many approaches to
chronic rejection. However, short-lived transgene
expression can also mediate long-lasting effects, especially
in the case when immunological tolerance toward donor
antigens can be induced (see below). The cellular target
should also be taken into account when choosing the vector.
While cardiomyocytes are the primary target of most gene
therapy approaches to acute rejection, endothelial cells and
other vascular cells are important targets for the prevention
of graft arteriopathy.
The number of cells that need to express the transgene in
order to achieve a biological effect depends on the delivered
gene itself. In the case when the gene encodes a secreted
peptide that acts on neighbouring cells via a paracrine
mechanism, limited numbers of gene-transduced cells may
be sufficient to elicit a therapeutic effect. What really
matters is the concentration of the protective gene product
within the graft, or in the plasma, depending on
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the mechanism of action. Conversely, in the case when the
therapeutic gene encodes an intracellular factor, as many
cardiac cells as possible should express the cytoprotective
molecule.
Replication-deficient, recombinant adenoviral vectors
have been used in the vast majority of gene therapy studies
for heart transplantation. These vectors efficiently transduce
genes into both cardiomyocytes and endothelial cells in vivo
[10–13]. Using a lac Z reporter gene, the b-galactosidase
gene product is readily visualized by histochemical reaction
with the chromogenic substrate X-gal (Fig. 1). It should be
noted, however, that the efficiency of gene transfer is
underestimated by X-gal staining due to lac Z expression
below the detection threshold in a proportion of cells [15].
Conversely, false-positive X-gal staining due to micro-
infarctions, rather than effective lac Z gene transfer, was
reported after intramyocardial injection [16].
Limitations of adenoviral vectors include tissue inflam-
mation and short-lived transgene expression (<2–4 weeks)
[12,17,18]. The absence of vector integration into the cell
genome, as well as immune responses to viral proteins are
responsible for the short duration of gene expression with
adenoviral vectors. Non-integrated DNA is inherently
unstable due to the presence of DNA digesting enzymes
within the cell. Immune responses include both cytotoxic
T cells that eliminate cells that express adenoviral antigens
and neutralizing antibody that preclude successful read-
ministration of the adenoviral vector [17]. By analogy,
pre-existing antibody as a result of previous infection with
wild-type adenovirus may preclude adenoviral gene transfer
in humans. In a cohort of healthy adult individuals, we
found a 57%-prevalence of neutralizing antibody to
adenovirus [17]. Thus, many candidate patients may be
refractory to adenovirus-based gene therapy. In a clinical
trial of gene therapy for coronary artery disease, the extent
of anti-adenovirus antibody formation in patients who
received intramyocardial adenoviral vectors was strongly
correlated with pre-existing antibodies [18].
Adenovirus-induced inflammation has been studied in
donor hearts transplanted into genetically identical hosts,
thus avoiding confounding alloimmune responses. Adeno-
virus-mediated lac Z gene transfer into rat cardiac isografts
caused significant myocardial inflammation that was
associated with rapid extinction of lac Z expression [19].
In contrast, negligible inflammation and long-lasting lac Z
expression were observed in adenovirally transduced mouse
cardiac isografts, despite the fact that the same vector
induced marked hepatic inflammation when administered to
the liver [20]. Although the differences between the two
organs have not been fully explained, the lower antigen-
presenting cell (APC) content of cardiac tissue, as compared
to the liver, may play a part. Dendritic cells as professional
APCs have been shown to migrate from the donor heart and
localize in the host’s spleen, where they generate productive
cellular and humoral immune responses [21].
Plasmid DNA, liposome–DNA and HVJ–liposome–
DNA vectors have also been used to deliver genes of interest
to the donor heart [13,14,22,23]. Although these vectors are
intrinsically less efficient than adenoviral vectors, they also
induce less tissue inflammation. Interestingly, those rare
studies that directly compared different vectors to each other
showed that the most efficient vector does not always mediate
the best therapeutic effect. For instance, liposome–DNA
transfection of the active form of transforming growth factor
(TGF)-b1 was more effective than adenovirus-mediated
Fig. 1. Adenovirus-mediated transfer of a lac Z reporter gene into a
transplanted rat heart. Cryosection through the heart shows patchy yet
widespread b-galactosidase expression (blue areas after X-gal staining),
most abundantly in the interventricular septum. It should be considered that
X-gal staining underestimates gene transfer efficiency [15]. Empty spaces
within myocardium are cyrosectioning artefacts. The apparent thickening
of the RV wall is an artefact due to the slightly oblique sectioning axis;
LV/RV, left/right ventricular cavities.
Fig. 2. Schematic of donor-specific hyporesponsiveness induced by
CTLA4-Ig gene transfer. A donor heart of the strain B transduced ex
vivo with the CTLA4-Ig gene and transplanted into the recipient strain A
survives indefinitely (.100 days). A second cardiac graft from the original
donor strain B is accepted in the absence of new treatment. In contrast, a
third-party graft from the strain C is rejected in the absence of treatment.
Modified from Ref. [7].
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gene transduction with respect to the prolongation of cardiac
allograft survival in mice [22]. HVJ–liposome vectors are
more efficient than most liposome and plasmid DNA vectors.
In addition, repeated gene transfer with these vectors is
feasible, and their safety profile is relatively good [23]. Thus,
HVJ–liposome–DNA complexes provide a useful alterna-
tive to adenoviral vectors for gene therapy applications in
heart transplantation.
Recombinant adeno-associated virus (AAV) vectors can
integrate into the host cell genome, thus providing a
potential for permanent genetic modifications of target
cells. We have shown that AAV-mediated expression of a
green fluorescence protein (GFP) reporter gene lasts for
extended periods of time (.1 year) in mouse myocardium
[6]. Attractive features of AAV vectors also include
negligible tissue inflammation and a good safety profile
because wild-type AAV is not a human pathogen. However,
delayed onset of expression (by ,1–2 weeks, as compared
to a few hours with adenoviral vectors [6]) limits the
usefulness of AAV vectors for applications in heart
transplantation. Nevertheless, AAV vectors could be used
in combination with immunosuppressive drugs to bridge the
gap from transplantation to onset of expression.
Retroviral vectors have been used only in a few studies of
heart transplantation because they do not efficiently
transduce genes into non-dividing cells such as cardio-
myocytes and the large majority of endothelial cells in
normal vessels. On the other hand, retroviral vectors have
been used to express donor major histocompatibility
complex (MHC) molecules in bone marrow cells to induce
donor-specific tolerance in the host [24]. Among retroviral
vectors, lentiviral vectors are unique in that they transduce
genes into both dividing and non-dividing cells. We have
shown that lentiviral vectors efficiently transduce and
express genes for extended periods of time (.10 weeks)
in adult rat myocardium [25]. The safety of the last
generation of lentiviral vectors is believed to be similar, if
not superior, to that of retroviral vectors used in clinical
trials of gene therapy. However, both vectors integrate at
non-specific sites in the cell genome. This raises the concern
of insertional mutagenesis, as discussed in the final section
of this review.
4. Gene transfer of cytoprotective factors
Several factors including brain death of the donor [26],
organ preservation, surgical stress, and ischaemia–reperfu-
sion injury [27] activate inflammatory cascades within the
graft in the first few hours and days after transplantation.
These alloantigen-independent insults to the graft up-
regulate adhesion molecules that mediate leucocyte
adhesion to the endothelium. During ischaemia–reperfu-
sion injury, oxidative stress, apoptosis (i.e. programmed cell
death) and pro-inflammatory cytokines cause early cell
damage which enhances subsequent alloresponses.
Gene transfer of cytoprotective, anti-inflammatory and
immunomodulatory molecules has been evaluated in heart
transplantation models in small animals (Table 1). Among
cytoprotective approaches, double-stranded oligodeoxynu-
cleotides with specific affinity for nuclear factor-kB (NF-kB
decoy), a transcriptional activator for adhesion molecule
genes, were tested in rat cardiac transplants [28]. After 16 h
of donor heart preservation at 4 8C in Euro-Collins solution
and 1 h of reperfusion, the NF-kB decoy significantly
reduced myocardial damage, as manifested by decreases in
serum creatine phosphokinase, tissue IL-8 and neutrophil
infiltration.
Table 1
Gene therapy for acute cardiac allograft rejection (non-exhaustive list)
Protective effect Therapeutic gene Biological activity Vector Model Ref.
Cardioprotection NFkB asDNA NFkB inhibition HVJ Rat [28]
eNOS NFkB inhibition Liposomes rabbit [29]
B2702, RDP1257 HO-1 activation Liposomes Mouse [33]
Anti-inflammatory TNFRp55-Ig TNFR inhibition Ad Rat [42]
IL-4 Th2 responses Ad Rat [52]
IL-10 T-cell apoptosis Ad, liposomes Rat, rabbit [48,49,51]
vIL-10 APC inhibition Liposomes retrovirus Rat, mouse [50,53]
IL-13 HO-1 activation Ad Rat [54]
TGF-b T-, B-cell inhibition Ad Rabbit [48]
IL-1RII-Ig IL-1 signaling inhibition Ad Rat [44]
vMIP-II, MC148 Chemokine blockade Liposomes Mouse [56]
8ND-RANTES Chemokine blockade Ad Rat [44]
Cell adhesion inhibition ICAM-1 asDNA ICAM-1 inhibition AS-ODN Rat [60]
T-cell suicide HSV-TK (þgancyclovir) Death of dividing T cells – Mouse [65]
Tolerance induction Donor MHC-I (þdonor cells) Donor-specific unresponsiveness Liposomes Ad Rat, mouse [68,69]
Inhibition of T-cell costimulation CTLA4-Ig B7 blockade Ad Rat [7,62,63]
CD40-Ig CD40 blockade Ad Rat [64]
Therapeutic genes and their mechanisms of action are shown. HVJ, hemagglutinating virus of Japan-liposome vector; Ad, adenoviral vector; AS-ODN,
anti-sense oligodeoxynucleotides. Other abbreviations: see text.
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An alternate approach involved endothelial nitric oxide
synthase (eNOS) gene transfer. eNOS catalyses the synthesis
of NO, a vasodilator molecule that plays key roles in
endothelial integrity and function, including inhibition of
neutrophil adhesion, platelet aggregation, and vascular
smooth muscle cell proliferation. Liposome-mediated
eNOS transfection was shown to reduce NFkB activation
and to delay cardiac allograft rejection in rabbits [29].
Heat shock proteins (HSPs) are physiologically up-
regulated as an adaptive response to ischaemia and
reperfusion. In a kidney transplantation model, heat shock
and recovery conferred protection to the donor organ against
ischaemia–reperfusion injury [30]. In native rat hearts,
HSP-70 gene transfection was associated with attenuated
ischaemia–reperfusion injury, as manifested by decreased
creatine phosphokinase release, increased mitochondrial
respiratory indices, and improved ventricular function [31].
By analogy, HSP gene transfer may be beneficial in heart
transplantation as well, although this needs to be directly
established.
Heme oxygenase (HO)-1 catalyses the rate-limiting step
in the degradation of heme to bilirubin. The enzyme has
potent anti-oxidant and anti-apoptotic effects. Enhanced
HO-1 activity after stimulation with cobalt protoporphyrin
prevented acute rejection and attenuated chronic rejection of
mouse cardiac allografts [32]. Consistently, gene transfer of
B2702 or RDP1257, two decapeptides that stimulate HO-1
activity, delayed cardiac allograft rejection in another study
[33]. Together, these results suggest that endogenous up-
regulation or exogenous overexpression of cytoprotective
genes mitigates ischaemia–reperfusion injury and acute
rejection.
5. Gene transfer of inhibitors of pro-inflammatory
cytokines
Alloimmune responses involve T-cell activation and
proliferation, cytokine production, natural killer (NK) cell
and B-cell activation, and antibody formation. T-helper (Th)
responses to antigen can be divided into type 1 (Th1) and
type 2 (Th2) [34]. Th1 responses include secretion of IL-2,
IL-12, interferon (IFN)-g, and generation of cytotoxic T
cells that recognize specific antigen. Th1 responses are
stimulated by IL-12 and IFN-g, and they are inhibited by
IL-4, IL-10 and TGF-b [35]. Th2 responses include IL-4
secretion and production of specific antibody to the antigen.
In long-term surviving grafts, decreases in Th1 cytokines
with concomitant increases in Th2 cytokines have
suggested the hypothesis that Th1 responses mediate acute
rejection, whereas Th2 responses may promote allograft
acceptance [36,37]. Data in mice deficient in the IFN-g,
IL-4, IL-10 or TGF-b genes lend support to this
hypothesis [38–41].
Tumor necrosis factor (TNF)-a and IL-1 act in
concert to activate T cells and vascular cells during
ischaemia–reperfusion injury. Targeting of the TNF-a
receptor by adenovirus-mediated TNFRp55-Ig gene transfer
resulted in decreased inflammation in rat cardiac allografts
[42]. Similarly, functional neutralization of the IL-1 type I
receptor by exogenous overexpression of IL-1 receptor
antagonist (IL-1Ra) protected native rat hearts against
ischaemia–reperfusion injury [43]. We took an alternate
approach to inhibit IL-1 signalling, namely gene transfer of
a soluble IL-1 type II receptor fused to human IgG1 heavy
chain (IL-1RII-Ig). The rationale for this approach is that the
non-signalling IL-1 type II receptor has a higher affinity for
IL-1b than the signalling type I receptor. Hence, soluble IL-
1RII-Ig acts as a scavenger for IL-1b. Adenovirus-mediated
IL-1RII-Ig gene transfer moderately prolonged cardiac
allograft survival in rats [44].
IL-17 and IL-18, originally termed IFN-g-inducing
factor, are pro-inflammatory cytokines involved in Th1
responses [45–47]. We have shown that adenovirus-
mediated gene transfer of either soluble IL-17 receptor-
IgG (IL-17R-Ig) or IL-18 binding protein (IL-18BP), the
naturally occurring inhibitor of IL-18 [47], delays cardiac
allograft rejection in rats (unpublished data). These
observations are consistent with data showing that
IL-17R-Ig protein treatment prolongs cardiac allograft
survival in mice [46]. The protective effect was associated
with impaired functional differentiation of dendritic cell
progenitors. Together, these results suggest that gene
transfer-based inhibition of pro-inflammatory cytokines
may slow down acute rejection, although it does not fully
prevent it. Incomplete protection presumably relates to the
redundancy of cytokine signalling pathways, whereby
multiple cytokines can activate the same inflammatory
cascades. This consideration implies that inhibition of an
individual cytokine may not be sufficient to suppress
alloimmune responses.
6. Gene transfer of immunomodulatory cytokines
Immunomodulatory cytokines such as IL-4, IL-10, IL-13
and TGF-b down-regulate Th1, while up-regulating Th2
responses [35]. Consistently, adenoviral transduction or
liposomal transfection of IL-4, IL-10, IL-13, or TGF-b
genes prolonged cardiac allograft survival in small animals
[22,48–53]. Exogenous IL-4 or IL-10 overexpression was
associated with Th2-dependent expression of protective
molecules [52,53]. Moreover, IL-10 gene transfer induced
apoptosis of alloreactive T cells via the Fas/Fas ligand
pathway and caused APC dysfunction within the allograft
[51,53]. IL-13 mediated immunomodulatory and anti-
apoptotic effects that were associated with HO-1 up-
regulation [54]. These results suggest that exogenous
overexpression of immunomodulatory cytokines may con-
fer partial protection against acute rejection.
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7. Gene transfer of chemokine inhibitors
Chemokines are a family of chemoattractant cytokines
that regulate leucocyte trafficking in inflammatory pro-
cesses. As such, chemokines play a key role in the
recruitment of lymphocytes and monocytes in the allograft
[55]. Monocyte chemoattractant protein (MCP)-1, IL-8 and
RANTES, among other chemokines, have been implicated
in allograft rejection. Interestingly, some viruses produce
chemokine homologues that inhibit leucocyte recruitment,
thereby allowing viruses to escape cellular immune
defences. Adenovirus-mediated gene transfer of the virally
encoded chemokine homologues vMIP-II or MC148
significantly delayed cardiac allograft rejection in mice
[56]. We obtained similar results with adenoviral vectors
expressing N-terminally deleted analogues of RANTES
[44] or MCP-1 (unpublished data). These truncated
analogues antagonize the respective full-length chemokines
for binding to their receptors [57]. Similarly to inhibitors of
pro-inflammatory cytokines, however, inhibitors of chemo-
kines delayed graft rejection only for limited periods of
time. Again, the incomplete effectiveness of these inhibitors
may be due to the redundancy of chemokine signalling
pathways. This concept refers to the fact that a leucocyte
population can be attracted by multiple chemokines, each of
which may bind to multiple receptors, and vice-versa [55].
Consequently, chemokine inhibition could be expected to
slow down leucocyte recruitment but not to suppress
rejection. In partial contrast to these considerations,
however, mice deficient in the CCR1 or CCR5 chemokine
receptors (which bind RANTES and other chemokines) did
not effectively reject cardiac allografts [58,59]. These data
suggest that chemokine inhibition may be of clinical
significance. On the other hand, the modest protection
conferred by adenovirus-mediated gene transfer of chemo-
kine inhibitors [44,56] may be due to suboptimal transgene
expression, rapid degradation of the gene product, and tissue
inflammation due to the adenoviral vector, which may
counteract the anti-inflammatory effects of chemokine
inhibition.
8. Gene transfer of adhesion molecule inhibitors
Adhesion molecules are up-regulated after heart trans-
plantation and mediate leucocyte adhesion to the luminal
surface of vascular endothelium. Hyperbaric transfection of
the donor heart with antisense oligodeoxynucleotides
specific for intercellular adhesion molecule (ICAM)-1, in
combination with a neutralizing antibody against leucocyte
function-associated antigen-1 (LFA-1), effectively pre-
vented cardiac allograft rejection in rodents [60]. These
results suggest that vascular adhesion molecules are major
targets of gene therapy for heart transplantation.
9. Gene transfer-based blockade of T-cell costimulatory
activation
Current immunosuppressive drugs block T-cell acti-
vation but do not eliminate alloreactive T cells. As a result,
alloimmune activity resumes if treatment is withdrawn. By
contrast, induction of immunological unresponsiveness, or
tolerance, toward donor antigens prevents generation of
alloreactive T cells. The physiological mechanisms under-
lying tolerance include central and peripheral T-cell
deletion and suppression, as well as anergy, which is
defined as unresponsiveness following restimulation with
the same antigen.
The concept of T-cell costimulatory activation is
important to understand anergy. This concept dictates that
two distinct signals are required for efficient T-cell
activation [61]. The first signal is mediated by the T-cell
receptor (TCR) occupied by antigenic peptides that are
presented on MHC molecules by APCs. The second signal
arises from interactions between costimulatory molecules
expressed on T cells and APCs. Costimulatory interactions
between CD28 and members of the B7 family, and between
CD40 ligand (CD154) and CD40 have been extensively
characterized. Antigenic peptide that occupies the TCR in
the absence of costimulatory activation induces antigen-
specific T-cell anergy. The T cell does not react to the
peptide it originally encountered in the absence of
costimulatory signals. However, the cell can react to other
antigens presented to it at earlier or later time points in the
presence of costimulatory activation.
CTLA-4 is up-regulated on activated T cells and
competes with CD28 for B7-1 and B7-2 binding, thereby
inhibiting costimulatory activation. A soluble CTLA-4
immunoglobulin fusion molecule (CTLA4-Ig) has been
evaluated as a treatment for autoimmune diseases and graft
rejection. Systemic CTLA4-Ig gene transfer or protein
treatment around the time of transplantation delayed cardiac
allograft rejection for limited periods of time (<20–30
days) in rodents [7,62,63]. In contrast, direct adenovirus-
mediated CTLA4-Ig gene transfer into the donor heart
resulted in indefinite cardiac allograft survival (.100 days)
in rats [7]. Intragraft and serum CTLA4-Ig levels were
detectable for more than 1 year after direct gene delivery to
the donor heart, whereas serum CTLA4-Ig levels rapidly
declined after systemic protein or gene administration. The
long-term persistence of CTLA4-Ig expression after
localized gene transfer might be due to inhibition of anti-
adenoviral immune responses in the presence of high
CTLA4-Ig concentrations. This highlights the possibility
that an immunomodulatory gene product promotes both
the persistence of transduced cells the gene product
itself and graft survival at the same time. Remarkably,
recipients of long-surviving grafts accepted a second
cardiac allograft from the original donor strain but rejected
third-party grafts, demonstrating donor-specific unrespon-
siveness (Fig. 2).
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Localized CTLA4-Ig gene transfer and systemic
CTLA4-Ig treatment had different impacts on the immune
system. Intragraft CTLA4-Ig expression reduced IL-2
receptor and MHC antigen expression, as well as humoral
and cellular immune responses against donor antigen and
cognate antigens in total splenocytes. Antibody production
against donor alloantigen and cognate antigens was
suppressed for more than 120 days. Both methods reduced
proliferative responses of graft-infiltrating cells and total
splenocytes to alloantigenic and mitogenic stimuli. How-
ever, localized CTLA4-Ig gene transfer did not affect
responses of lymph node cells and T cells purified from
splenocytes, whereas systemic CTLA4-Ig treatment did.
Thus, generalized immunocompetence was essentially
preserved with localized CTLA4-Ig gene transfer.
Adenovirus-mediated CD40-Ig gene transfer was used to
block the CD40/CD154 costimulatory pathway. Exogenous
overexpression of soluble CD40-Ig mediated indefinite
(.200 days) cardiac allograft survival in rats [64]. These
results underline the remarkable potential of gene therapy
strategies that block T-cell costimulatory activation.
10. Gene transfer of T-cell suicide molecules
Gene transfer of suicide genes such as herpes simplex
virus thymidine kinase (TK) has been used to kill
proliferating cells selectively. TK converts the nucleoside
analogue gancyclovir into gancyclovir-monophosphate,
which is then converted into gancyclovir-triphosphate and
incorporated into elongating DNA, causing death of
dividing cells. Transgenic mice that express TK in their T
cells have been used as an experimental model to evaluate
the usefulness of suicide gene-approaches for heart
transplantation. In TK-transgenic mice, a 7-day gancyclovir
course around the time of transplantation resulted in donor-
specific unresponsiveness and long-lasting allograft survi-
val, in the absence of generalized immunosuppression [65].
Similar approaches have been used in clinical trials of
hematopoietic stem cell transplantation, where gancyclovir
controlled graft-versus-host disease caused by TK trans-
genic T cells [66]. Of course, suicide gene-approaches to
heart transplantation would require complex protocols
including administration of autologous genetically modified
T cells after a T cell-depleting immunosuppressive regimen.
An attractive aspect, however, is that gancyclovir treatment
would be needed only in the first few days after
transplantation.
11. Gene transfer of donor-specific MHC class I
molecules
Donor-specific MHC class I gene transfer to the host has
also been used to induce immunological unresponsiveness
to the allograft [24,67]. Retrovirus-mediated gene transfer
of soluble donor MHC class I molecules into the thymus or
bone marrow cells resulted in prolonged allograft survival in
a high-responder heart transplantation model [68]. Simi-
larly, adenovirus-mediated gene transfer of a single donor-
specific MHC class I molecule into bone marrow cells, in
combination with transient depletion of CD4þ cells,
mediated long-lasting survival of fully allogeneic cardiac
grafts, in the absence of detectable microchimerism [69].
12. Gene therapy for chronic rejection (graft
arteriosclerosis)
Accelerated graft arteriopathy is one of the most
discouraging aspects of clinical transplantation [2,3].
Coronary artery lesions in transplanted hearts develop at a
,20-fold higher pace compared to naturally occurring
arteriosclerosis. Vascular endothelium is the first donor-
derived tissue encountered by the host’s circulating lympho-
cytes, and alloresponses to donor antigens expressed on
endothelial cells have been implicated in the pathogenesis of
graft arteriopathy. Anti-endothelial antibodies are
detectable in the sera of a significant proportion of patients
with the disease [70]. An important role for humoral
immune mechanisms is also supported by data in B cell-
deficient mice, which show attenuated graft arteriopathy
[71]. However, data in mice with different forms of
profound immune deficiencies suggest that both antigen-
dependent and independent (innate) cellular responses are
also involved [71–73]. These responses differ between
acute and chronic rejection. A clinical association between
acute and chronic rejection has been established in kidney
transplantation but is still controversial in heart transplan-
tation [74,75]. A non-exhaustive list of gene therapy
approaches to chronic rejection is shown in Table 2.
Gene transfer-based blockade of T-cell costimulatory
activation was evaluated both in aortic and in cardiac
models of graft arteriopathy. CD40-Ig gene transfer reduced
alloreactive antibody formation, leucocyte infiltrates in the
arterial wall, and intimal thickening in rat aortic allografts
[76]. In contrast, CD40-Ig gene transfer did not prevent graft
arteriopathy in rat cardiac allografts, despite preserving
them from acute rejection [64]. These results are consistent
with data in mice deficient in CD40 ligand. These mice do
not acutely reject cardiac allografts but develop arterio-
pathic lesions in their coronary arteries [77].
An alternate approach to graft arteriopathy involves gene
transfer of soluble Fas. The rationale for this approach is
that activation of the death receptor Fas by Fas ligand,
which is triggered by activated macrophages, mediates
vascular cell death in graft coronary arteries. Soluble Fas
sequesters Fas ligand, thereby inhibiting Fas activation on
vascular cells. Gene transfer of soluble Fas significantly
reduced arteriopathic lesions in rat aortic allografts [78].
Similar results were obtained by either endogenous or
exogenous overexpression of HO-1, an enzyme with
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anti-oxidant and anti-apoptotic activities, in cardiac and
aortic allografts, respectively [32,79].
Antisense oligonucleotides specific for the Bcl-x gene
were tested in mouse cardiac allografts. Bcl-x inhibits
apoptotic cell death of proliferating vascular smooth muscle
cells that are responsible for intimal thickening. Targeting of
Bcl-x reduced coronary artery lesions in mouse allografts [80].
Tissue plasminogen activator (tPA), a fibrinolytic factor
also involved in wound healing, is down-regulated in
transplant arteriosclerosis. Intracoronary tPA gene transfec-
tion with cationic liposomes attenuated arteriopathic lesions
in rabbit cardiac allografts [81].
Finally, promising results were obtained by targeting the
transcription factor E2F, which plays a central role in the
transcription of multiple cell-cycle regulatory genes. Up-
regulation of these genes in vascular smooth muscle cells
promotes cell proliferation and intimal thickening in graft
coronary arteries. Ex vivo transfection of the donor heart
with double-stranded DNA with specific affinity for E2F
(E2F decoy) prevented graft neointima formation for up to 8
weeks both in mice and in non-human primates [82].
13. Gene therapy for tolerance induction
Tolerance was first described 50 years ago as a state of
immunological unresponsiveness toward antigens to which
the immune system was exposed during the embryonic or
neonatal period, which was maintained by the continuous
presence of the antigens [83]. In transplantation immuno-
logy, tolerance refers to specific non-reactivity to graft
alloantigens in the absence of ongoing therapy. In the
clinical setting, however, tolerance does not mean complete
unresponsiveness to the graft, but rather a lack of destructive
alloresponses in an immunocompetent host [84]. Sporadic
clinical cases of spontaneous allograft tolerance have been
reported. A few patients stopped immunosuppression with-
out losing their graft, and occasional patients treated by total
body irradiation as induction therapy for transplantation
maintained their graft in the absence of immunosuppression
[85,86]. However, some of these reports were subsequently
revised due to graft loss at late follow-up [85].
Tolerogenic protocols include bone marrow chimerism
[87], in vitro manipulated or immature donor dendritic cells
[88], T-cell costimulatory blockade [7,64,89], and T-cell
depleting agents [90]. However, development of clinically
suitable non-myeloablative regimens that allow bone
marrow transplantation and long-lasting chimerism in
HLA-mismatched patients is a difficult task [84]. Blockade
of T-cell costimulatory activation may represent a more
practical option. Recently, this approach has been tested in
preclinical studies of organ transplantation and in clinical
trials of bone marrow transplantation and autoimmune
diseases. Short-term treatment with a humanized anti-
CD154 antibody prevented acute renal allograft rejection
in non-human primates [89]. CTLA4-Ig protein treatment
showed some beneficial effects in patients with autoimmune
psoriasis vulgaris or bone marrow transplantation [91,92]
but not in those with systemic lupus erythematosus [93].
Several gene therapy studies claimed tolerance induction
based on long-lasting cardiac allograft survival (.100 days)
with acceptance of a second graft from the original donor
strain in rodents [7,64,65]. However, these results should be
cautiously considered as evidence for prolonged donor-
specific unresponsiveness, rather than true tolerance. It is
still unclear whether or not blockade of T-cell costimulatory
activation can establish tolerance on its own. This approach
is likely most effective when the size of the T-cell
population that needs to be tolerized is small, which is not
the case in organ transplantation [84]. Concomitant use of
adjunct strategies involving donor antigens or dendritic cells
may be required to induce sustained tolerance to cardiac
allografts [94]. For instance, the combination of an anti-
CD154 monoclonal antibody plus donor cells suppressed
graft arteriopathy in mouse cardiac allografts [32].
Recently, novel T-cell costimulatory pathways involving
ICOS/B-7h, CD134/CD134L, CD27/CD70, and PD-1/PD-
L1 interactions have been identified. The complexity of
these pathways suggests that treatment with multiple
costimulatory inhibitors may be more effective than
individual inhibitors.
An additional issue that is still unresolved is the
relationship between tolerance and graft arteriopathy. As a
manifestation of chronic rejection, graft arteriopathy would
Table 2
Gene therapy for graft arteriosclerosis (non-exhaustive list)
Protective effect Therapeutic gene Biological activity Vector Model Ref.
Anti-apoptosis Soluble Fas Fas blockade Ad Rat aorta [78]
HO-1 Anti-oxidant Ad Rat aorta [79]
Bcl-x Anti-apoptotic AS-ODN Mouse heart [80]
Cell cycle regulation E2F AS-DNA E2F inhibition HVJ Mouse, monkey hearts [82]
Inhibition of T-cell costimulation CD40-Ig CD40 blockade Ad Rat aorta [76]
Anti-thrombotic (?) tPA Fibrinolysis (?) Liposomes Rabbit heart [81]
Successfully tested protective genes acting by different mechanisms are shown. HVJ, hemagglutinating virus of Japan-liposome vector; Ad, adenoviral
vector; AS-ODN DNA, anti-sense oligodeoxynucleotides. Other abbreviations: see text.
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not be expected to occur in tolerant hosts. However, a recent
study by Russell et al. questioned this assumption [73]. In
this study, two methods were used to tolerize recipient mice:
‘classical’ tolerance was induced by neonatal administration
of allogeneic spleen cells, whereas bone marrow was
infused to suitably prepared adult recipients to produce
‘mixed chimerism’. Both methods induced states of
profound tolerance, as manifested by donor-specific accep-
tance of cardiac and skin grafts, and undetectable specific
antibody in all recipients. In both groups, however, cardiac
grafts developed striking proliferative lesions in their
coronary arteries. These results came as a surprise. The
authors concluded that incompatibilities, at least of MHC-
determined antigens, are sufficient to trigger graft vasculo-
pathy in the absence of any demonstrable immune activity,
either cellular or humoral. They speculated that the innate or
primitive pathway of responsiveness that involves cyto-
toxicity and cytokine release by NK cells could be
responsible for graft arteriopathy in tolerant animals. In
another study, tolerance induction by infusion of donor bone
marrow cells, in combination with a short cyclosporine
course, prevented graft arteriopathy in rat cardiac trans-
plants [95]. Similarly, tolerance induction by donor-specific
kidney transplants plus a short cyclosporine course
prevented arterial lesion formation in cardiac allografts in
mini-swine [96]. These inconsistencies in results are
difficult to explain but the variability in innate responsive-
ness among species and differences between the tolerogenic
protocols could play a part. To sum up, induction of clinical
tolerance remains a major challenge. Even if this goal can
be achieved, this may not necessarily translate into complete
protection against graft arteriopathy. Safety issues regarding
the risk of tolerance induction toward infectious agents
present at the time of treatment and the long-term risk of
malignancies also need to be addressed.
14. Limitations of gene therapy studies
Despite significant advances in transplantation immuno-
logy, the clinical reality is still characterized by ineffective
treatments for chronic rejection. The failure of gene therapy
for heart transplantation to give rise to clinical applications
may be accounted for by several factors. First, most studies
have been devoted to acute rejection, for which effective
treatments already exist, whereas fewer investigations have
focused on graft vasculopathy, which is the more relevant
clinical target. Second, most studies did not compare gene
therapy approaches and established treatments. Third, the
vast majority of gene therapy studies were performed in
rodents; however, results in rodents are often not applicable
to humans [84]. For instance, the absence of MHC class II
molecules on mouse endothelium may ease allograft
acceptance in this species. By contrast, genes encoding
TCR and MHC proteins are well conserved between rhesus
monkeys and humans. Both species express MHC class I
and II molecules on endothelial cells and reject vascularized
grafts in a similar manner [88,97]. Unfortunately, only few
data regarding gene therapy for heart transplantation in non-
human primates are available [82].
15. Future perspectives
It is difficult to forecast when clinical applications in
gene therapy for heart transplantation can be initiated.
Preclinical studies that compare gene therapy approaches
with established treatments in non-human primates are
needed before clinical trials can be started. Because of the
lack of reliable clinical predictors of graft arteriosclerosis,
all transplanted patients would need to be treated in order to
prevent the disease in a subgroup of them. This implies that
new treatments should be highly effective and safe. With
respect to gene therapy, fundamental questions regarding
the most efficient vector system, the best therapeutic gene,
and safety issues remain unanswered. While constitutively
active promoters have been used to drive transgene
expression in experimental studies, regulatable promoters
that permit to adjust gene expression to the clinical needs
offer major advantages for clinical applications. These
promoters make ‘gene dosage’ possible, for instance by oral
administration of a drug (e.g. tetracycline) that modulates
promoter activity [98]. Should side effects occur, regula-
table vectors could be ‘switched off’. In principle,
physiological regulation of the therapeutic effect by an
endogenous marker of the disease is also feasible. An
example was provided by gene transfer of the V2
vasopressin receptor, which stimulates myocardial contrac-
tility, into failing rabbit hearts [99]. Because the endogenous
ligand, arginine vasopressin, is increased in heart failure,
activation of the transgenic receptor correlates with the
severity of the disease. However, further improvements in
regulated gene transfer systems are needed before they can
be considered for gene therapy applications.
The gene therapy field has been criticized for promising
too much and yielding too little. Most recently, the first
severe adverse events in clinical trials of gene therapy came
like dark clouds in a blue sky. A teenager died in 1999 soon
after receiving adenovirus-based gene therapy for treatment
of partial ornithine transcarbamylase (OTC) deficiency
[100]. The patient suffered from a mild form of the disease,
an X-linked defect of the urea cycle in which nitrogen
metabolism is affected, resulting in neurological symptoms.
After receiving the highest dose of the vector in the trial, the
patient became comatose, developed acute respiratory
distress syndrome and died 2 days later of multiple organ
failure. Although the precise cause of the death remained
unclear, an unusually strong inflammatory reaction to the
adenoviral vector was involved. It should be emphasized,
however, that early-generation adenoviral vectors like the
one administered in this trial are now likely to be phased out
for most diseases [100]. Novel adenoviral vectors deleted in
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most or all viral genes have been developed [101]. We have
shown that these so-called gutless vectors efficiently
transduce genes into rat myocardium, while causing
decreased inflammation compared to conventional adeno-
viral vectors (unpublished data).
Two serious adverse events occurred in a clinical trial of
gene therapy for inherited, X chromosome-linked, severe
combined immune deficiency (X-SCID) caused by common
gamma (gamma-c) gene mutations. This trial involved
retrovirus-mediated gamma-c gene transfer into marrow
CD34þ cells [102]. In the summer of 2002, one of the
patients treated with this vector developed a lymphocytosis
during a viral infection, followed by a lymphoproliferative
syndrome. In December 2002, a second case of leukaemia-
like illness was detected [103]. In both cases, hyperprolifer-
ating cells were found to bear an insertion of the vector near
the proto-oncogene Lmo2. The emergence of a second case
of vector insertion at the same location near the proto-
oncogene raised further concerns about insertional muta-
genesis as a result of random vector integration into the cell
genome [104]. However, the absence of this problem in
previous studies and trials suggests that peculiar factors
including the gene and vector used and the immunodeficient
state of the patients may have favoured these adverse events.
As a result of these adverse events, 27 gene therapy trials were
put on hold in the United States. Researchers are now going
back to the bench to further investigate the risks associated with
these approaches. Meanwhile, novel vectors that integrate at
specific chromosomal locations have been developed to
minimize the risk of insertional mutagenesis [105].
In conclusion, like any other new treatment, gene therapy
was not expected to advance without adverse events.
Notwithstanding, the potential of this approach to organ
transplantation appears to be essentially intact, as genetic
modification of the donor organ remains an appealing
strategy. Recent advances in transplantation immunology,
cardiac biology and gene delivery technology have
improved our perspectives for clinical applications in this
field.
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